Recombinant Erythropoietin

Erythropoietin is a hormone produced in the kidney influencing the rate of production of red blood cells in the body.

Recombinant Erythropoietin medications (rH-EPO) are primarily used to treat anemia and additional condition associated with or resulting from cancer and cancer therapy.

rH-EPO are commonly indicated for patients suffering from anemia (chronic kidney disease and chemotherapy), inflammatory bowel disease and myelodysplasia (chemotherapy and radiation).

The range of rH-EPO products include Epoetin alfa, beta, lambda, zeta, theta and Darbepoetin.

All rH-EPO products are manufactured in a cGMP state of the art EU/FDA approvable facility based on rDNA technology from E. coli cells.

The Products are formulated in vials and prefilled syringes with various concentrations; and can be supplied diluted or in sterile powder for dilution, with CTD dossier.

rH-EPO are also available in bulk ABS form for compounding and filling in third parties’ facilities, with DMF.